What is Confluence Discovery Technologies?
Confluence Discovery Technologies, founded in 2010 and headquartered in St. Louis, Missouri, is a business-to-business pharmaceutical company dedicated to advancing drug discovery and development. Operating across multiple sites, the company places a paramount emphasis on scientific research and pioneering innovation within the medical and health industries. Confluence Discovery Technologies offers specialized consulting services and harnesses its extensive scientific acumen to provide sophisticated pharmaceutical solutions tailored to client needs.
How much funding has Confluence Discovery Technologies raised?
Confluence Discovery Technologies has raised a total of $11.2M across 3 funding rounds:
Series A
$4M
Unspecified
$2.4M
Private Equity
$4.8M
Series A (2012): $4M with participation from BioGenerator, Missouri Technology, DFJ Mercury, and Helix Funds
Unspecified (2015): $2.4M led by BioGenerator, Epidarex Capital, Missouri Technology, Mercury Fund, and St Louis Arch Angels
Private Equity (2016): $4.8M, investors not publicly disclosed
Key Investors in Confluence Discovery Technologies
BioGenerator
BioGenerator is an organization based in St. Louis, Missouri, focused on creating and growing innovative companies through investment and comprehensive startup support, particularly in the life sciences sector.
Missouri Technology
The Missouri Technology Corporation (MTC) is a public-private partnership supporting new high-tech companies in Missouri, with a focus on life sciences and technology, offering venture capital and grants.
DFJ Mercury
DFJ Mercury, part of the global Draper Fisher Jurvetson network, is a venture capital firm that invests in extraordinary entrepreneurs, particularly in technology sectors, aiming to drive significant market change.
What's next for Confluence Discovery Technologies?
The substantial enterprise-level funding and recent strategic investment indicate Confluence Discovery Technologies is likely in a growth or scaling phase, aiming to expand its research capabilities, clinical trial support, or market reach. This capital infusion is expected to fuel further advancements in its drug discovery pipeline and enhance its service offerings to pharmaceutical clients. The company's focus on scientific rigor and innovation suggests a strategic direction towards developing novel therapeutic solutions and solidifying its position as a key player in the competitive pharmaceutical services landscape.
See full Confluence Discovery Technologies company page
